Scarica l'app Stockscreener
30.56
9.29%
-3.13
Dopo l'orario di chiusura:
31.25
0.69
+2.26%
Precedente Chiudi:
$33.69
Aprire:
$32.64
Volume 24 ore:
4.27M
Relative Volume:
2.86
Capitalizzazione di mercato:
$3.93B
Reddito:
-
Utile/perdita netta:
$-507.65M
Rapporto P/E:
-6.6435
EPS:
-4.6
Flusso di cassa netto:
$-616.24M
1 W Prestazione:
-56.82%
1M Prestazione:
-57.61%
6M Prestazione:
-72.49%
1 anno Prestazione:
-53.06%
Intervallo 1D:
$30.00
$33.05
Intervallo di 1 settimana:
$30.00
$71.22
Portata 52W:
$30.00
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Nome
Vaxcyte Inc
Settore
Industria
Telefono
650-837-0111
Indirizzo
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Confronta PCVX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
30.56 | 3.93B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Iniziato | Goldman | Buy |
| 2023-12-07 | Iniziato | Mizuho | Buy |
| 2023-04-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-03 | Reiterato | Needham | Buy |
| 2022-12-15 | Iniziato | Guggenheim | Buy |
| 2022-11-17 | Iniziato | BTIG Research | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-24 | Ripresa | Jefferies | Buy |
| 2020-07-07 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Iniziato | Needham | Buy |
Mostra tutto
Vaxcyte Inc Borsa (PCVX) Ultime notizie
InvestingPro Fair Value model correctly predicted Vaxcyte’s decline By Investing.com - Investing.com UK
(PCVX) Investment Analysis - news.stocktradersdaily.com
Vaxcyte (PCVX) Stock Falls 45% Despite Positive Vaccine Trial Re - GuruFocus
Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI - Yahoo Finance
BofA lowers Vaxcyte price target, says selloff after infant data ‘overdone’ - TipRanks
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Vaxcyte stock sinks despite Phase II IPD vaccine trial success - Yahoo Finance
Vaxcyte stock up on results from mid-stage trial of its pneumococcal vaccine - MSN
Vaxcyte’s Promising Vaccine Potential and Market Expansion Drive Buy Rating - TipRanks
Goldman Sachs cuts Vaxcyte stock price target to $100 - Investing.com
Goldman Sachs cuts Vaxcyte stock price target to $100 By Investing.com - Investing.com UK
Vaxcyte’s Strong Phase 2 Data and Future Prospects Justify Buy Rating Despite Market Overreaction - TipRanks
Vaxcyte price target lowered to $90 from $140 at Needham - MSN
Vaxcyte sights set on next results after ‘big moment’ with PCV - BioWorld MedTech
Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (NASDAQ:PCVX) - Seeking Alpha
Sector Update: Health Care Stocks Higher Late Afternoon - MarketScreener
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (NASDAQ:PCVX) - Seeking Alpha
Jefferies maintains Buy on Vaxcyte stock, price target at $146 By Investing.com - Investing.com Canada
Vaxcyte’s VAX-24: Promising Infant Vaccine Results Amidst Investor Concerns - TipRanks
Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials - TipRanks
Vaxcyte falls as pneumococcal vaccine data fails to meet lofty investor expectations - TradingView
Jefferies maintains Buy on Vaxcyte stock, price target at $146 - Investing.com India
Daily Digest: Large Asian grocer T&T Supermarket to land in S.F.; Vaxcyte stock plunges - The Business Journals
Biotech Stocks Hammered After A Key FDA Official Resigns - Investor's Business Daily
Vaxcyte stock touches 52-week low at $33.19 amid market shifts - Investing.com
Vaxcyte VAX-24 Vaccine Data Missed Wall Street Expectations, But Fundamentally Still Positive, Mizuho Securities Says - MarketScreener
Guggenheim maintains Vaxcyte stock Buy rating, $160 target By Investing.com - Investing.com Canada
Guggenheim maintains Vaxcyte stock Buy rating, $160 target - Investing.com India
Vaxcyte reports topline results from VAX-24 infant Phase 2 dose-finding study - TipRanks
Vaxcyte plunges despite pneumonia shot results as Marks departure weighs (PCVX:NASDAQ) - Seeking Alpha
Sector Update: Health Care Stocks Fall Pre-Bell Monday - MarketScreener
Vaxcyte’s VAX-24 shows promise in infant vaccine study By Investing.com - Investing.com South Africa
Vaxcyte Announces Positive Phase 2 Results for VAX-24 - TipRanks
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine - Benzinga
S&P 500 Futures Fall in Premarket Trading; Vaxcyte, Moderna Lag - Barron's
Vaxcyte's Pneumococcal Conjugate Vaccine Candidate Shows Substantial Immune Response in Infants - Marketscreener.com
Vaxcyte stock tumbles following Phase 2 study results By Investing.com - Investing.com Australia
Vaxcyte Announces Positive Topline Results From VAX-24 Infant Phase 2 Dose-Finding Study - MarketScreener
Vaxcyte stock tumbles following Phase 2 study results - Investing.com
Vaxcyte’s VAX-24 shows promise in infant vaccine study - Investing.com
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study - GlobeNewswire
Breakthrough: Vaxcyte's New Vaccine Shows Promise in Phase 2 Infant Trial - Stock Titan
Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now - Yahoo Finance
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - GlobeNewswire
First Look: Vaxcyte Reveals Phase 2 Data for Next-Gen Infant Pneumococcal Vaccine - Stock Titan
Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Real Estate Deals of the Year: Vaxcyte lease is a Deal of the Year - The Business Journals
Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? - MSN
Vaxcyte (PCVX) Struggled Amid Political Uncertainty - Insider Monkey
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans - simplywall.st
Guggenheim Reaffirms Buy Rating for Vaxcyte (NASDAQ:PCVX) - Defense World
Vaxcyte Inc Azioni (PCVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):